Welcome to our dedicated page for Pharmather Holdings news (Ticker: PHRRF), a resource for investors and traders seeking the latest updates and insights on Pharmather Holdings stock.
PharmaTher Holdings Ltd. develops specialty pharmaceutical platforms centered on microneedle drug delivery. Company updates focus on PharmaPatch™ product programs for ketamine, psychedelics, GLP-1 drugs and therapeutic peptides, along with PatchPrint™, its automated tabletop microneedle patch 3D printer designed to support end-to-end patch manufacturing.
Recurring news themes include U.S. patent applications for patch manufacturing and peptide formulations, expansion of the PharmaPatch™ platform into new drug categories, regulatory and policy developments affecting ketamine, psychedelics and peptides, and the company's retained economic participation tied to its previously approved and sold U.S. generic ketamine ANDA.
PharmaTher (OTCQB:PHRRF) announced that Sairiyo Therapeutics, 49% owned by PharmaTher, is advancing its patented oral cepharanthine formulation PD-001 as a potential candidate for Hantavirus-related diseases.
Independent research found cepharanthine inhibited Hantavirus pseudovirus infection in mice by about 92–94% at 45–180 mg/kg/day. PD-001 has Australian ethics approval for a first-in-human Phase 1 trial in healthy volunteers to assess safety and pharmacokinetics only. PharmaTher emphasizes PD-001 is not proven to treat or prevent Hantavirus or any infectious disease, and future development depends on Phase 1 results, further data, regulatory review, financing, and manufacturing readiness.
PharmaTher (OTCQB: PHRRF) says a U.S. executive order on accelerating treatments for serious mental illness (April 18, 2026) could create a more supportive regulatory backdrop for its ketamine programs. The company highlights its KetaVault partnership portal, a completed IND‑enabling PK/tolerability study for a ketamine microneedle patch, retained ketamine programs, and ongoing upside from a prior FDA‑approved ketamine ANDA sale that may generate more than US$25 million over time, subject to commercial performance.
PharmaTher (OTCQB: PHRRF) says its PatchPrint™ automated microneedle manufacturing platform and PharmaPatch™ product platform could benefit from two U.S. regulatory shifts: a presidential executive order accelerating psychedelic treatments and an FDA/HHS move to reclassify therapeutic peptides with an advisory meeting on July 23–24, 2026.
The company highlights completed IND‑enabling work for a ketamine patch, provisional U.S. patent filings for peptide candidates and PatchPrint™, and potential commercial pathways for compounding pharmacies and hospitals.
PharmaTher (OTCQB: PHRRF) supports a proposed U.S. peptide reclassification and links the potential policy change to increased commercial relevance for its PharmaPatch microneedle delivery and PatchPrint manufacturing platform.
The company notes the FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee agenda lists BPC-157, KPV and TB-500—peptides already on PharmaTher's roadmap—and cites a provisional patent filed April 13, 2026 for stabilized peptide formulations for microneedle delivery.
PharmaTher (OTCQB: PHRRF) filed U.S. provisional patent application No. 64/034,315 on April 13, 2026 for "Stabilized Peptide Compositions for Microneedle and Transdermal Delivery." The filing aims to protect formulation approaches to improve peptide stability, shelf life, manufacturing compatibility and layered microneedle designs for PharmaPatch while complementing PatchPrint manufacturing.
Claims include polymers, sugars, amino acids, buffers, layered tip/backing designs, low-moisture packaging, and support for multiple peptide categories and combined-peptide dosage forms.
PharmaTher (OTCQB: PHRRF) filed a provisional USPTO patent (Application No. 64/015,408) on March 26, 2026 for PatchPrint, an automated tabletop microneedle patch 3D printer that integrates dispensing, vacuum loading, drying, demolding and packaging.
The company is pursuing commercialization, engineering partnerships, peptide patch development, branded wellness products and partner-facing manufacturing services to scale its PharmaPatch programs.
PharmaTher (OTCQB: PHRRF) announced a strategic initiative on March 3, 2026 to expand its PharmaPatch™ microneedle platform into select therapeutic peptides for the U.S. market.
The company cited prior ketamine, psychedelics and GLP-1 patch work, named initial candidates (BPC-157, GHK-Cu, TB-500, KPV), referenced a large U.S. peptide market (US$65.1B 2024 to ~US$160.3B by 2030, 14.7% CAGR), and noted staged R&D, regulatory monitoring, and investigational status with no FDA approvals.
PharmaTher (OTCQB: PHRRF) announced a strategic initiative to seek Health Canada approval for generic semaglutide and, if approved, commercialize in Canada. Regulatory exclusivity expired in January 2026, opening a pathway for generics. The plan targets Health Canada approval in 2026 with broad dose coverage (0.25 mg–2.4 mg) and a sterile injectable manufacturing strategy audited by regulators. The company cites prior U.S. FDA approval and monetization of ketamine rights with potential proceeds exceeding US$25 million, and notes Ozempic generated an estimated C$2.9 billion in Canadian sales in 2025.
PharmaTher (OTCQB: PHRRF) announced a strategic initiative to apply its PharmaPatch™ microneedle patch platform to GLP-1 therapies for obesity on January 14, 2026. The company cites prior pre-IND work and published research on ketamine and psychedelic patches to support controlled, sustained delivery and flexible dosing.
PharmaTher aims to develop a needle-free, at-home microneedle patch with potential delivery of up to one month from a single application, will pursue feasibility and preclinical studies, and expects to file a patent application later this month. The release highlights a cited U.S. obesity market forecast of $11.2B in 2024 rising to $48.5B by 2030.
PharmaTher (OTCQB: PHRRF) published a January 2, 2026 letter from CEO Fabio Chianelli outlining 2025 milestones and 2026 priorities. Key 2025 achievements included FDA approval of Ketamine ANDA #217858, the sale and December 2025 closing of that ANDA under a deal with upfronts, sales milestones and profit‑sharing potentially exceeding US$25 million, and reduced cash burn entering 2026.
For 2026 the company plans to: realize economics from the ANDA sale, pursue ex‑U.S. ketamine commercialization and partnerships (Parkinson's and drug delivery), evaluate a long‑acting injectable program via an Oakwood agreement, and crystallize value from its 49% equity interest in Sairiyo Therapeutics.